Jinghua Pharmaceutical Group Co Ltd banner

Jinghua Pharmaceutical Group Co Ltd
SZSE:002349

Watchlist Manager
Jinghua Pharmaceutical Group Co Ltd Logo
Jinghua Pharmaceutical Group Co Ltd
SZSE:002349
Watchlist
Price: 7.61 CNY 0.4% Market Closed
Market Cap: ¥6.2B

Relative Value

The Relative Value of one Jinghua Pharmaceutical Group Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 7.61 CNY, Jinghua Pharmaceutical Group Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Jinghua Pharmaceutical Group Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Jinghua Pharmaceutical Group Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Jinghua Pharmaceutical Group Co Ltd
SZSE:002349
6.3B CNY 4.4 28.1 19.7 19.7
US
Eli Lilly and Co
NYSE:LLY
964.4B USD 14.8 46.7 31.5 33.5
US
Johnson & Johnson
NYSE:JNJ
572.6B USD 6.1 21.4 14.9 18.2
CH
Roche Holding AG
SIX:ROG
284.3B CHF 4.6 30 12.7 14.8
US
Merck & Co Inc
NYSE:MRK
297.7B USD 4.6 16.3 10.2 11.9
CH
Novartis AG
SIX:NOVN
228.8B CHF 5.2 21.1 13 16.7
UK
AstraZeneca PLC
LSE:AZN
217.7B GBP 5.2 32 15.3 22.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.8 9.4 11
US
Pfizer Inc
NYSE:PFE
151.1B USD 2.4 19.4 7.3 9.7
US
Bristol-Myers Squibb Co
NYSE:BMY
120.9B USD 2.5 20 7.1 9.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Jinghua Pharmaceutical Group Co Ltd
SZSE:002349
Average EV/EBITDA: 43.1
19.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.5
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.4
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
US
Merck & Co Inc
NYSE:MRK
10.2
7%
1.5
CH
Novartis AG
SIX:NOVN
13
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
15.3
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.4
7%
1.3
US
Pfizer Inc
NYSE:PFE
7.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-9%
N/A